Sign In
Section Navigation
Common TitleINROADS
Official Title A Multicenter, Single Arm, Open-Label Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients
Phase Phase II
ClinicalTrials.gov NCT01199939
Treatments
Darunavir
Darunavir Prezista

Darunavir

Tradename:PrezistaOther Names:DRVClass:Protease Inhibitors (PI)
,
Etravirine
Etravirine Intelence

Etravirine

Tradename:IntelenceOther Names:ETRClass:Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Categories Resistance/Virological FailureTreatment-NaiveTreatment-ExperiencedDual Therapy
Funding
IndustryJanssen
References
  • Ruane PJ, Brinson C, Ramgopal M, et al. The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects. HIV Med. 2015;16:288-96.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.